Medtech Insight caught up with Deltex Medical CEO Andy Mears during the Medica 2024 exhibition and conference in Düsseldorf, Germany, where the UK SME was profiling its TrueVue technology and taking the opportunity to meet international distributors for current and future business expansion.
Niche Innovator Deltex Medical On Market Access, EU MDR And A Mission To Change The World
TrueVue Oesophageal Doppler Monitor Developer Guards Its Space In A Market Characterized By Multinationals
The UK market has become tougher for smaller innovators, says Andy Mears, CEO of Deltex Medical, which plans to launch a new iteration of its minimally invasive ultrasound-based technology, the oesophageal Doppler monitor. He explained how market access challenges have steepened.
More from Startups & SMEs
More from Medtech Insight
• By
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
• By
Exer Labs Inc.’s website marketed its AI-based Exer Scan app to “screen and treat Parkinson’s, TB, Cerebral Palsy and more.” But those claims went well beyond what was allowed under the product’s 510(k) clearance, US regulators say.